Stemina Biomarker Discovery Inc., is rebranding its diagnostics to more accurately represent its focus on neurological disorders, the company announced recently.

According to a release, NeuroPointDX, a division of Stemina, will use its metabolomics platform and proprietary biomarker database to diagnose, treat and develop new therapies for neurological disorders. It is already being implemented in the largest clinical study conducted of the metabolism of children with autism spectrum disorder (ASD).

Stemina also announced Kevin Krenitsky, president of Opgen, has joined the board of directors.

“Dr. Krenitsky will be a key contributor to our business strategy for NeuroPointDX,” Stemina CEO Elizabeth Donley said in a statement.

As previously reported, Stemina received a $2.7 million grant. Some of the funds will be used to validate NeuroPointDX’ diagnostic test for ASD from a small blood sample.